FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Feinglos

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Concepts & Ideas

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
Mary Elizabeth Cox; Mark N Feinglos
Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes.
Miriam Amiram; Mark N Feinglos; Xinghai Li; Kelli M Luginbuhl; Ashutosh Chilkoti
Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control.
Elizabeth Marrett; Larry Radican; Qiaoyi Zhang; Michael J Davies; Claudia Kanitscheider; Mark N Feinglos
Physician reasons for nonpharmacologic treatment of hyperglycemia in older patients newly diagnosed with type 2 diabetes mellitus.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Feinglos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mary Elizabeth Cox; Mark N Feinglos
Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes.
Current diabetes reports 2013;13(3):319-28.
2013: Miriam Amiram; Mark N Feinglos; Xinghai Li; Kelli M Luginbuhl; Ashutosh Chilkoti
Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(8):2792-7.
2012: Elizabeth Marrett; Larry Radican; Qiaoyi Zhang; Michael J Davies; Claudia Kanitscheider; Mark N Feinglos
Physician reasons for nonpharmacologic treatment of hyperglycemia in older patients newly diagnosed with type 2 diabetes mellitus.
Diabetes therapy : research, treatment and education of diabetes and related disorders 2012;3(1):5.
2012: Marcelo B Andrade; Adrien J Di Domizio; Mark N Feinglos; Shaunna M Morrison; Robert T Downs
Robertsite, Ca(2)Mn(III) (3)O(2)(PO(4))(3)·3H(2)O.
Acta crystallographica. Section E, Structure reports online 2012;68(Pt 10):i74-i75.
2010: Frank A Sloan; Mark N Feinglos; Daniel S Grossman
Receipt of care and reduction of lower extremity amputations in a nationally representative sample of U.S. Elderly.
Health services research 2010;45(6 Pt 1):1740-62.
2010: Richard S Surwit; Redford B Williams; James D Lane; Mark N Feinglos; Cynthia M Kuhn; Anastasia Georgiades
Plasma epinephrine predicts fasting glucose in centrally obese African-American women.
Obesity (Silver Spring, Md.) 2010;18(9):1683-7.
2010: Michael E Miller; Denise E Bonds; Hertzel C Gerstein; Elizabeth R Seaquist; Richard M Bergenstal; Jorge Calles-Escandon; R Dale Childress; Timothy E Craven; Robert M Cuddihy; George Dailey; Mark N Feinglos; Farmarz Ismail-Beigi; Joe F Largay; Patrick J O'Connor; Terri Paul; Peter J Savage; Ulrich Schubart; Ajay Sood; Saul Genuth
The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
BMJ (Clinical research ed.) 2010;340():b5444.
2009: Jessica Shill; M Angelyn Bethel; Mark N Feinglos
Algorithm: management of diabetes mellitus: dietary and drug therapy.
Postgraduate medicine 2009;121(4):170-1.
2009: Jessica Shill; M Angelyn Bethel; Mark N Feinglos
Algorithm: management of diabetes mellitus.
Postgraduate medicine 2009;121(4):169.
2009: Richard S Surwit; James D Lane; David S Millington; Haoyue Zhang; Mark N Feinglos; S Minda; Rhonda Merwin; Cynthia M Kuhn; Raymond C Boston; Anastasia Georgiades
Hostility and minimal model of glucose kinetics in African American women.
Psychosomatic medicine 2009;71(6):646-51.
2009: Anastasia Georgiades; James D Lane; Stephen H Boyle; Beverly H Brummett; John C Barefoot; Cynthia M Kuhn; Mark N Feinglos; Redford B Williams; Rhonda Merwin; S Minda; Ilene Siegler; Richard S Surwit
Hostility and fasting glucose in African American women.
Psychosomatic medicine 2009;71(6):642-5.
2008: Jessica E Shill; Mark N Feinglos; Edward C Suarez
Offspring of patients with diabetes exhibit a clustering of psychosocial distress and inflammatory and metabolic risk factors.
Diabetes care 2008;31(11):e86.
2008: Mark N Feinglos; Susan E Totten
Are you what you eat, or how much you eat? The case of type 2 diabetes mellitus.
Archives of internal medicine 2008;168(14):1485-6.
2008: James D Lane; Mark N Feinglos; Richard S Surwit
Caffeine increases ambulatory glucose and postprandial responses in coffee drinkers with type 2 diabetes.
Diabetes care 2008;31(2):221-2.
2008: Frank A Sloan; M Angelyn Bethel; David Ruiz; Alisa M Shea; Alisa H Shea; Mark N Feinglos
The growing burden of diabetes mellitus in the US elderly population.
Archives of internal medicine 2008;168(2):192-9; discussion 199.
2008: Jennifer Green; Mark N Feinglos
New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
Vascular health and risk management 2008;4(4):743-51.
2007: Jennifer B Green; Mark N Feinglos
Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
Current diabetes reports 2007;7(5):369-75.
2007: J Green; Mark N Feinglos
Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm.
International journal of clinical practice. Supplement 2007;(154):3-11.
2007: Barry J Goldstein; Mark N Feinglos; Jared K Lunceford; Jeremy Johnson; Debora E Williams-Herman
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Diabetes care 2007;30(8):1979-87.
2007: Hertzel C Gerstein; Matthew C Riddle; David M Kendall; Robert M Cohen; Robin Goland; Mark N Feinglos; Julienne K Kirk; Bruce P Hamilton; Faramarz Ismail-Beigi; Patricia Feeney
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
The American journal of cardiology 2007;99(12A):34i-43i.
2007: M Angelyn Bethel; Frank A Sloan; Daniel Belsky; Mark N Feinglos
Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients.
Archives of internal medicine 2007;167(9):921-7.
2007: James D Lane; Allen L Hwang; Mark N Feinglos; Richard S Surwit
Exaggeration of postprandial hyperglycemia in patients with type 2 diabetes by administration of caffeine in coffee.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2007;13(3):239-43.
2007: Anastasia Georgiades; Nancy Zucker; Kelli E Friedman; Christopher J Mosunic; Katherine L Applegate; James D Lane; Mark N Feinglos; Richard S Surwit
Changes in depressive symptoms and glycemic control in diabetes mellitus.
Psychosomatic medicine 2007;69(3):235-41.
2006: Jennifer B Green; Mark N Feinglos
Are sulfonylureas passé?
Current diabetes reports 2006;6(5):373-7.
2005: Beverly H Brummett; Ilene Siegler; William M Rohe; John C Barefoot; Peter P Vitaliano; Richard S Surwit; Mark N Feinglos; Redford B Williams
Neighborhood characteristics moderate effects of caregiving on glucose functioning.
Psychosomatic medicine 2005;67(5):752-8.
2005: Mark N Feinglos; M Angelyn Bethel
Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals.
Cleveland Clinic journal of medicine 2005;72(9):791-9.
2005: Mark N Feinglos; M F Saad; F X Pi-Sunyer; B An; O Santiago
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2005;22(8):1016-23.
2005: Lillian F Lien; Susan E Spratt; Zinta Woods; Kim K Osborne; Mark N Feinglos
Optimizing hospital use of intravenous insulin therapy: improved management of hyperglycemia and error reduction with a new nomogram.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2005;11(4):240-53.
2005: Richard S Surwit; Miranda A L van Tilburg; Priti I Parekh; James D Lane; Mark N Feinglos
Treatment regimen determines the relationship between depression and glycemic control.
Diabetes research and clinical practice 2005;69(1):78-80.
2005: Carlos D Sánchez; L Kristin Newby; Darren K McGuire; Vic Hasselblad; Mark N Feinglos; Erik Ohman
Diabetes-related knowledge, atherosclerotic risk factor control, and outcomes in acute coronary syndromes.
The American journal of cardiology 2005;95(11):1290-4.
2005: M Angelyn Bethel; Mark N Feinglos
Basal insulin therapy in type 2 diabetes.
The Journal of the American Board of Family Practice / American Board of Family Practice 2005;18(3):199-204.
2005: Mark N Feinglos; G Dailey; W Cefalu; K Osei; J Tayek; W Canovatchel; R Chaiken; Ione A Kourides
Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.
Diabetes research and clinical practice 2005;68(2):167-75.
2005: Lillian F Lien; Mark N Feinglos
Protease inhibitor-induced diabetic complications : incidence, management and prevention.
Drug safety : an international journal of medical toxicology and drug experience 2005;28(3):209-26.
2004: M Angelyn Bethel; John Alexander; Jim Lane; Christina Barkauskas; Mark N Feinglos
Diabetes on a cardiovascular ward: adherence to current recommendations.
Southern medical journal 2004;97(11):1031-7.
2004: James D Lane; Christina E Barkauskas; Richard S Surwit; Mark N Feinglos
Caffeine impairs glucose metabolism in type 2 diabetes.
Diabetes care 2004;27(8):2047-8.
2004: Lillian F Lien; M Angelyn Bethel; Mark N Feinglos
In-hospital management of type 2 diabetes mellitus.
The Medical clinics of North America 2004;88(4):1085-105, xii.
2004: Frank A Sloan; M Angelyn Bethel; Paul P Lee; Derek S Brown; Mark N Feinglos
Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes.
The review of diabetic studies : RDS 2004;1(1):29-38.
2004: G de L Dear; Neal W Pollock; Donna M Uguccioni; J Dovenbarger; Mark N Feinglos; Richard E Moon
Plasma glucose responses in recreational divers with insulin-requiring diabetes.
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc 2004;31(3):291-301.
2003: Lana L Watkins; Andrew Sherwood; Mark N Feinglos; Alan L Hinderliter; Michael A Babyak; Elizabeth C D Gullette; Robert Waugh; James A Blumenthal
Effects of exercise and weight loss on cardiac risk factors associated with syndrome X.
Archives of internal medicine 2003;163(16):1889-95.
2002: M Angelyn Bethel; Mark N Feinglos
Insulin analogues: new therapies for type 2 diabetes mellitus.
Current diabetes reports 2002;2(5):403-8.
2002: Richard S Surwit; Redford B Williams; Ilene Siegler; James D Lane; Michael J Helms; Katherine L Applegate; Nancy Zucker; Mark N Feinglos; Cynthia M McCaskill; John C Barefoot
Hostility, race, and glucose metabolism in nondiabetic individuals.
Diabetes care 2002;25(5):835-9.
2002: Richard S Surwit; Miranda A L van Tilburg; Nancy Zucker; Cynthia C McCaskill; Priti I Parekh; Mark N Feinglos; Christopher L Edwards; Paula Williams; James D Lane
Stress management improves long-term glycemic control in type 2 diabetes.
Diabetes care 2002;25(1):30-4.
2001: B Luna; Mark N Feinglos
Drug-induced hyperglycemia.
JAMA : the journal of the American Medical Association 2001;286(16):1945-8.
2001: Miranda A L van Tilburg; Cynthia C McCaskill; James D Lane; Christopher L Edwards; A Bethel; Mark N Feinglos; Richard S Surwit
Depressed mood is a factor in glycemic control in type 1 diabetes.
Psychosomatic medicine 2001;63(4):551-5.
2001: B Luna; Mark N Feinglos
Oral agents in the management of type 2 diabetes mellitus.
American family physician 2001;63(9):1747-56.
2000: James D Lane; Cynthia C McCaskill; P G Williams; Priti I Parekh; Mark N Feinglos; Richard S Surwit
Personality correlates of glycemic control in type 2 diabetes.
Diabetes care 2000;23(9):1321-5.
2000: James A Blumenthal; Andrew Sherwood; Elizabeth C D Gullette; Michael A Babyak; Robert Waugh; Anastasia Georgiades; L W Craighead; Damon Tweedy; Mark N Feinglos; M Appelbaum; Junichiro Hayano; Alan L Hinderliter
Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning.
Archives of internal medicine 2000;160(13):1947-58.
1999: B Luna; A T Hughes; Mark N Feinglos
The use of insulin secretagogues in the treatment of type 2 diabetes.
Primary care 1999;26(4):895-915.
1999: Mark N Feinglos; M Angelyn Bethel
Therapy of type 2 diabetes, cardiovascular death, and the UGDP.
American heart journal 1999;138(5 Pt 1):S346-52.
1999: Sunil V Rao; M Angelyn Bethel; Mark N Feinglos
Treatment of diabetes mellitus: implications of the use of oral agents.
American heart journal 1999;138(5 Pt 1):S334-7.
1999: Mark N Feinglos; M Angelyn Bethel
Oral agent therapy in the treatment of type 2 diabetes.
Diabetes care 1999;22 Suppl 3():C61-4.
1998: Priti I Parekh; Ann Petro; J M Tiller; Mark N Feinglos; Richard S Surwit
Reversal of diet-induced obesity and diabetes in C57BL/6J mice.
Metabolism: clinical and experimental 1998;47(9):1089-96.
1998: Mark N Feinglos; M Angelyn Bethel
Treatment of type 2 diabetes mellitus.
The Medical clinics of North America 1998;82(4):757-90.
1998: Mark N Feinglos; C R Thacker; B Lobaugh; D D DeAtkine; D B McNeill; J S English; D L Bursey
Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.
Diabetes research and clinical practice 1998;39(3):193-9.
1997: Mark N Feinglos; C H Thacker; J English; M Angelyn Bethel; James D Lane
Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Diabetes care 1997;20(10):1539-42.
1997: Nicole E Jelesoff; Mark N Feinglos; C B Granger; Robert M Califf
Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials.
Journal of cardiovascular risk 1997;4(2):100-11.
1997: Richard S Surwit; Mark N Feinglos; Cynthia C McCaskill; S L Clay; M A Babyak; B S Brownlow; Claudia Plaisted Fernandez; Pao-Hwa Lin
Metabolic and behavioral effects of a high-sucrose diet during weight loss.
The American journal of clinical nutrition 1997;65(4):908-15.
1996: B S Brownlow; Ann Petro; Mark N Feinglos; Richard S Surwit
The role of motor activity in diet-induced obesity in C57BL/6J mice.
Physiology & behavior 1996;60(1):37-41.
1996: Emmanuel C Opara; Ann Petro; A Tevrizian; Mark N Feinglos; Richard S Surwit
L-glutamine supplementation of a high fat diet reduces body weight and attenuates hyperglycemia and hyperinsulinemia in C57BL/6J mice.
The Journal of nutrition 1996;126(1):273-9.
1995: S K Lee; Emmanuel C Opara; Richard S Surwit; Mark N Feinglos; O E Akwari
Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice.
Pancreas 1995;11(2):206-11.
1995: H E Wencel; C Smothers; Emmanuel C Opara; Cynthia M Kuhn; Mark N Feinglos; Richard S Surwit
Impaired second phase insulin response of diabetes-prone C57BL/6J mouse islets.
Physiology & behavior 1995;57(6):1215-20.
1995: Richard S Surwit; Mark N Feinglos; J Rodin; A Sutherland; Ann Petro; Emmanuel C Opara; Cynthia M Kuhn; M Rebuffé-Scrive
Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice.
Metabolism: clinical and experimental 1995;44(5):645-51.
1994: Michael F Seldin; D Mott; D Bhat; Ann Petro; Cynthia M Kuhn; Stephen Kingsmore; C Bogardus; Emmanuel C Opara; Mark N Feinglos; Richard S Surwit
Glycogen synthase: a putative locus for diet-induced hyperglycemia.
The Journal of clinical investigation 1994;94(1):269-76.
1994: E G Livingston; Mark N Feinglos; C M Kuhn; C Secor; Richard S Surwit
Hyperinsulinemia in the pregnant C57BL/6J mouse.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1994;26(6):307-8.
1993: M Rebuffé-Scrive; Richard S Surwit; Mark N Feinglos; C Kuhn; J Rodin
Regional fat distribution and metabolism in a new mouse model (C57BL/6J) of non-insulin-dependent diabetes mellitus.
Metabolism: clinical and experimental 1993;42(11):1405-9.
1993: James D Lane; Cynthia C McCaskill; S L Ross; Mark N Feinglos; Richard S Surwit
Relaxation training for NIDDM. Predicting who may benefit.
Diabetes care 1993;16(8):1087-94.
1993: E Mills; C M Kuhn; Mark N Feinglos; Richard S Surwit
Hypertension in CB57BL/6J mouse model of non-insulin-dependent diabetes mellitus.
The American journal of physiology 1993;264(1 Pt 2):R73-8.
1992: S J Schwab; F L Dunn; Mark N Feinglos
Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis.
Diabetes care 1992;15(11):1581-4.
1992: Richard S Surwit; M S Schneider; Mark N Feinglos
Stress and diabetes mellitus.
Diabetes care 1992;15(10):1413-22.
1992: Mark N Feinglos; Richard S Surwit; Cynthia C McCaskill; S L Ross
Plasma levels of beta-endorphin and adrenocorticotropic hormone in IDDM and NIDDM.
Diabetes care 1992;15(4):590-1.
1991: Richard S Surwit; Michael F Seldin; Cynthia M Kuhn; C Cochrane; Mark N Feinglos
Control of expression of insulin resistance and hyperglycemia by different genetic factors in diabetic C57BL/6J mice.
Diabetes 1991;40(1):82-7.
1989: Shin Fukudo; S Virnelli; Cynthia M Kuhn; C Cochrane; Mark N Feinglos; Richard S Surwit
Muscarinic stimulation and antagonism and glucoregulation in nondiabetic and obese hyperglycemic mice.
Diabetes 1989;38(11):1433-8.
1989: J A McCubbin; Richard S Surwit; Cynthia M Kuhn; C Cochrane; Mark N Feinglos
Naltrexone potentiates glycemic responses during stress and epinephrine challenge in genetically obese mice.
Psychosomatic medicine 1989;51(4):441-8.
1989: Richard S Surwit; J A McCubbin; Cynthia M Kuhn; C Cochrane; Mark N Feinglos
Differential glycemic effects of morphine in diabetic and normal mice.
Metabolism: clinical and experimental 1989;38(3):282-5.
1988: E M Morrell; Richard S Surwit; Cynthia M Kuhn; Mark N Feinglos; C Cochrane
Classically conditioned enhancement of hyperinsulinemia in the ob/ob mouse.
Psychosomatic medicine 1988;50(6):586-90.
1988: Richard S Surwit; Cynthia M Kuhn; C Cochrane; J A McCubbin; Mark N Feinglos
Diet-induced type II diabetes in C57BL/6J mice.
Diabetes 1988;37(9):1163-7.
1988: Richard S Surwit; Mark N Feinglos
Stress and autonomic nervous system in type II diabetes. A hypothesis.
Diabetes care 1988;11(1):83-5.
1987: Cynthia M Kuhn; C Cochrane; Mark N Feinglos; Richard S Surwit
Exaggerated peripheral responses to catecholamines contributes to stress-induced hyperglycemia in the ob/ob mouse.
Pharmacology, biochemistry, and behavior 1987;26(3):491-5.
1986: Richard S Surwit; J A McCubbin; Cynthia M Kuhn; D McGee; D Gerstenfeld; Mark N Feinglos
Alprazolam reduces stress hyperglycemia in ob/ob mice.
Psychosomatic medicine 1986;48(3-4):278-82.
1985: Richard S Surwit; J A McCubbin; E G Livingston; Mark N Feinglos
Classically conditioned hyperglycemia in the obese mouse.
Psychosomatic medicine 1985;47(6):565-8.
1984: Richard S Surwit; Mark N Feinglos; E G Livingston; Cynthia M Kuhn; J A McCubbin
Behavioral manipulation of the diabetic phenotype in ob/ob mice.
Diabetes 1984;33(7):616-8.